As the second largest biopharmaceutical market, China presents tremendous opportunity, but companies will need to mature medical affairs teams quickly as the market continues to evolve. To strengthen their medical affairs teams, pharmaceutical companies will need to be creative with their physician and stakeholder engagement models, as well as cultivating the local talent.

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.